Charles Cashion is Director at NovaBay Pharmaceuticals, Inc. (NBY). They have made 1 open-market trade across 1 company since 2009, most recently 2017-01-09.
CIK 0001410079
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2K since 2009, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBY | BUY | 2009-08-31 | 2009-08-31 | $1.90 | $2K | +12.3% | +3.6% | +3.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.